| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
NOS
|
Business associate |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2018-09-01 | N/A | Cronos and Ginkgo announced an agreement to produce cultured cannabinoids. | N/A | View |
This document is page 21 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing a strategic partnership between Cronos Group and Ginkgo Bioworks valued at $122MM. The text details the financial structure of the deal, including R&D funding and equity milestones for producing specific cannabinoids like THC and CBD. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, likely included in a larger cache of internal financial documents.
This document is page 19 of a Cowen 'Collaborative Insights' report dated February 25, 2019. It details the industry landscape for synthetic biology cannabinoid production, listing specific companies such as Ginkgo Bioworks and Amyris with brief descriptions of their technologies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, though no direct mention of Jeffrey Epstein appears on this specific page.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity